ArriVent BioPharma Inc.
AVBP | NASDAQ
$29.74
+$0.84 (+2.91%)
At close: Sep 21, 2026, 4:00 PM ET
$29.51
-$0.23 (-0.77%)
Pre-market:
Sep 22, 2026, 7:31 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 |
|---|---|---|---|---|---|
Net Income | -166.31M | -80.49M | -69.33M | -36.91M | -51.61M |
Depreciation & Amortization | n/a | n/a | n/a | n/a | n/a |
Stock-Based Compensation | 12.52M | 3.21M | 895K | 424K | 66.67K |
Other Working Capital | -5.92M | 7.82M | 11.22M | -9.95M | -4.23M |
Other Non-Cash Items | -3.03M | n/a | n/a | n/a | 42.89M |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | -3.77M | 7.07M | 12.6M | -7.15M | -3.94M |
Operating Cash Flow | -160.59M | -70.21M | -55.84M | -43.63M | -12.59M |
Capital Expenditures | n/a | n/a | n/a | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | -272.93M | -194.16M | -25M | n/a | n/a |
Sales Maturities Of Investments | 201.71M | 1.7M | 25M | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | -40M |
Investing Cash Flow | -71.23M | -192.47M | n/a | n/a | -40M |
Debt Repayment | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | -70K | 631K | -2.41M | 15K | n/a |
Financial Cash Flow | 203.06M | 186.58M | 42.86M | 169.72M | 89.87M |
Net Cash Flow | -28.75M | -76.1M | -12.98M | 126.09M | 37.28M |
Free Cash Flow | -160.59M | -70.21M | -55.84M | -43.63M | -12.59M |
Adj. Free Cash Flow | -173.11M | -73.42M | -56.74M | -44.06M | -12.65M |
Maintenance CapEx | n/a | n/a | n/a | n/a | n/a |
Growth CapEx | n/a | n/a | n/a | n/a | n/a |
Owner Earnings | -160.59M | -70.21M | -55.84M | -43.63M | -12.59M |
Add to Watchlist
Select watchlists to add or remove AVBP